JMKX 000197
Alternative Names: JMKX-000197Latest Information Update: 18 Apr 2025
At a glance
- Originator Jemincare
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Malignant pleural effusion
- Preclinical Bladder cancer
- Research Head and neck cancer
Most Recent Events
- 28 Dec 2024 Phase-I clinical trials in Malignant pleural effusion (Late-stage disease) in China (unspecified route) (NCT06740019)
- 18 Dec 2024 Jemincare plans a phase Ib trial for Malignant Pleural Effusions (Late-stage disease) in China (Injection), in December 2024 (NCT06740019)
- 26 Dec 2023 Preclinical trials in Bladder cancer in China, USA prior to December 2023